Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis by PIK3CA and ESR1 mutation status from circulating tumor DNA

被引：1
|
作者：
Dickler, M. N.
Saura, C.
Oliveira, M.
Richards, D. A.
Krop, I. E.
Cervantes, A.
Stout, T. J.
Jin, H.
Savage, H. M.
Wilson, T. R.
Baselga, J.
机构：
[1] Mem Sloan Kettering Canc Ctr, Mem Hosp, 1275 York Ave, New York, NY 10021 USA
[2] Vall Hebron Univ Hosp, Vall Hebron Inst Oncol, Barcelona, Spain
[3] US Oncol Res, The Woodlands, TX USA
[4] Dana Farber Canc Inst, Boston, MA USA
[5] Univ Valencia, Inst Hlth Res INCLIVA, Valencia, Spain
[6] Genentech Inc, San Francisco, CA 94080 USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P6-12-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-12-01
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Circulating tumor DNA analysis for ESR1 mutations in patients with hormone receptor-positive metastatic breast cancer
    Sim, Sung Hoon
    Jeon, Su Yeon
    An, Kyoung Hee
    Kong, Sun Young
    Kwon, Min Jung
    Lee, Keun Seok
    Park, In Hae
    CANCER RESEARCH, 2018, 78 (13)
  • [22] Final Overall Survival Analysis of Monarch 2: A Phase 3 trial of Abemaciclib Plus Fulvestrant in Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
    Llombart-Cussac, Antonio
    Sledge, George
    Toi, Masakazu
    Neven, Patrick
    Sohn, Joo Hyuk
    Inoue, Kenichi
    Pivot, Xavier
    Okera, Meena
    Masuda, Norikazu
    Kaufman, Peter A.
    Koh, Han
    Grischke, Eva-Maria
    Conte, PierFranco
    Andre, Valerie
    Bian, Yuanyuan
    Shahir, Ashwin
    van Hal, Gertjan
    CANCER RESEARCH, 2023, 83 (05)
  • [23] Preliminary correlative analysis of clinical outcomes with PIK3CA mutation (mut) status from a phase I/Ib study of GDC-0077 in patients (pts) with hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC)
    Jhaveri, Komal
    Juric, Dejan
    Varga, Andrea
    Turner, Nicolas
    Schmid, Peter
    Saura, Cristina
    Oliveira, Mafalda
    Krop, Ian E.
    Kalinsky, Kevin
    Italiano, Antoine
    Hamilton, Erika
    Gambardella, Valentina
    Cervantes, Andres
    Bedard, Philippe L.
    Liu, Bonnie P.
    Chen, Jessica W.
    Aimi, Junko
    Royer-Joo, Stephanie
    Schutzman, Jennifer L.
    Hutchinson, Katherine E.
    CANCER RESEARCH, 2021, 81 (04)
  • [24] Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
    D. Bello Roufai
    A. Gonçalves
    T. De La Motte Rouge
    S. Akla
    C. Blonz
    J. Grenier
    J. Gligorov
    M. Saghatchian
    C. Bailleux
    H. Simon
    I. Desmoulins
    Z. Tharin
    E. Renaud
    M. Bertho
    M-A Benderra
    S. Delaloge
    L. Robert
    P. Cottu
    J. Y. Pierga
    D. Loirat
    A. Bertucci
    B. Renouf
    F. C. Bidard
    F. Lerebours
    Oncogene, 2023, 42 : 1417 - 1417
  • [25] Baseline circulating ESR1 mutation analysis in the randomised phase III EFECT study of fulvestrant versus exemestane in advanced hormone receptor positive breast cancer
    Turner, N.
    Swift, C.
    Kilburn, L.
    Garcia-Murillas, I.
    Johnston, S.
    Budzar, A.
    Robertson, J.
    Gradishar, W.
    Piccart, M.
    Schiavon, G.
    Chia, S.
    CANCER RESEARCH, 2019, 79 (04)
  • [26] PIK3CA mutation analysis in circulating tumor cells of patients with hormone receptor positive metastatic breast cancer
    Marino, Elena
    Mauro, Cristian
    Belloni, Elena
    Picozzi, Marco
    Favalli, Valentina
    Cassatella, Maria Cristina
    Zorzino, Laura
    Giaco, Luciano
    Pelicci, Pier Giuseppe
    Barberis, Massimo
    Sandri, Maria Teresa
    Bernard, Loris
    BIOCHEMISTRY AND BIOPHYSICS REPORTS, 2024, 39
  • [27] Circulating tumor DNA dynamics in acelERA Breast Cancer: a Phase II study of giredestrant for estrogen receptor-positive, HER2-negative, previously treated advanced breast cancer
    Collier, Ann
    Bardia, Aditya
    Sohn, Joo Hyuk
    Lim, Elgene
    Chavez, Marianna
    Martin, Miguel
    Martinalbo, Jorge
    Perez-Moreno, Pablo
    Moore, Heather
    CANCER RESEARCH, 2024, 84 (09)
  • [28] Circulating tumor DNA (ctDNA) analysis of PIK3CA and AKT1 mutations in patients enrolled onto the Phase 1b study of the PI3K inhibitor taselisib (GDC-0032) in solid malignancies
    Wilson, Timothy R.
    Savage, Heidi
    Aimi, Junko
    Jin, Jessica
    Parmar, Hema
    Hsu, Jerry
    Krop, Ian
    Saura, Cristina
    Cervantes, Andres
    Sachdev, Jasgit
    Patel, Manish
    Cejalvo, Juan
    Oliveira, Mafalda
    Winer, Eric
    Von Hoff, Daniel
    Baselga, Jose
    Juric, Dejan
    CANCER RESEARCH, 2015, 75
  • [29] A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast Cancer
    Cescon, David W.
    Hilton, John
    Morales Murilo, Serafin
    Layman, Rachel M.
    Pluard, Timothy
    Yeo, Belinda
    Park, In Hae
    Provencher, Louise
    Kim, Sung-Bae
    Im, Young-Hyuck
    Wyce, Anastasia
    Krishnatry, Anu Shilpa
    Hicks, Kirsty
    Zhang, Qu
    Barbash, Olena
    Khaled, Ahmed
    Horner, Thierry
    Dhar, Arindam
    Oliveira, Mafalda
    Sparano, Joseph A.
    CLINICAL CANCER RESEARCH, 2024, 30 (02) : 334 - 343
  • [30] Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.
    Baselga, Jose
    Dent, Susan Faye
    Cortes, Javier
    Im, Young-Hyuck
    Dieras, Veronique
    Harbeck, Nadia
    Krop, Ian E.
    Verma, Sunil
    Wilson, Timothy R.
    Jin, Huan
    Wang, Lijia
    Schimmoller, Frauke
    Hsu, Jerry Y.
    He, Jing
    DeLaurentiis, Michelino
    Drullinsky, Pamela
    Jacot, William
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18)
12345